Invasive Pneumococcal Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major invasive pneumococcal disease markets reached a value of US$ 6.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.0 Billion by 2034, exhibiting a growth rate (CAGR) of 5.13% during 2024-2034.
The invasive pneumococcal disease market has been comprehensively analyzed in IMARC's new report titled "Invasive Pneumococcal Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Invasive pneumococcal disease refers to a severe infection caused by the bacterium Streptococcus pneumoniae, commonly known as pneumococcus. This ailment primarily affects the respiratory system but can also lead to bloodstream infections (septicemia) and various other life-threatening complications. The symptoms of the illness can vary widely, ranging from high fever, chills, cough, and difficulty breathing to chest pain, stiff neck, rapid heart rate, sensitivity to light, and confusion. The diagnosis of invasive pneumococcal disease typically involves a comprehensive combination of clinical findings, imaging studies, and laboratory tests. The healthcare provider often recommends blood cultures to identify the presence of pneumococcus in the bloodstream. Furthermore, chest X-rays might be performed to visualize any potential lung involvement in individuals suffering from the ailment. Additionally, samples from numerous other affected sites, such as cerebrospinal fluid in cases of meningitis, could be analyzed to confirm the presence of the bacterium and guide appropriate treatment.
The increasing cases of bacterial infections, in which the microorganism invades the bloodstream or tissues and fluids surrounding the spinal cord and brain, are primarily driving the invasive pneumococcal disease market. In addition to this, the inflating utilization of effective medication, including broad-spectrum antibiotics, such as penicillin, cephalosporins, macrolides, etc., to combat the ailment and prevent its spread, is also creating a positive outlook for the market. Moreover, the widespread adoption of pneumococcal vaccines, encompassing conjugate and polysaccharide vaccines, is further bolstering the market growth. These therapeutic vaccines aid in safeguarding individuals of various age groups against numerous strains of the bacterium, thereby reducing the incidence of severe pneumococcal infections. Apart from this, the rising application of supportive therapies, such as oxygen supplementation, fluid management, respiratory support, etc., for enhancing treatment outcomes in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced diagnostic tools like polymerase chain reaction (PCR), which can help in early detection and accurate characterization of the ailment, is also augmenting the market growth. Furthermore, numerous ongoing advancements in the field of innovative therapeutic techniques, with a focus on antibody-mediated therapies and antitoxin interventions, are expected to drive the invasive pneumococcal disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the invasive pneumococcal disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for invasive pneumococcal disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the invasive pneumococcal disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the invasive pneumococcal disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the invasive pneumococcal disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current invasive pneumococcal disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the invasive pneumococcal disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the invasive pneumococcal disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the invasive pneumococcal disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of invasive pneumococcal disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of invasive pneumococcal disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of invasive pneumococcal disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with invasive pneumococcal disease across the seven major markets?
What is the size of the invasive pneumococcal disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of invasive pneumococcal disease?
What will be the growth rate of patients across the seven major markets?
Invasive Pneumococcal Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for invasive pneumococcal disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the invasive pneumococcal disease market?
What are the key regulatory events related to the invasive pneumococcal disease market?
What is the structure of clinical trial landscape by status related to the invasive pneumococcal disease market?
What is the structure of clinical trial landscape by phase related to the invasive pneumococcal disease market?
What is the structure of clinical trial landscape by route of administration related to the invasive pneumococcal disease market?
The invasive pneumococcal disease market has been comprehensively analyzed in IMARC's new report titled "Invasive Pneumococcal Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Invasive pneumococcal disease refers to a severe infection caused by the bacterium Streptococcus pneumoniae, commonly known as pneumococcus. This ailment primarily affects the respiratory system but can also lead to bloodstream infections (septicemia) and various other life-threatening complications. The symptoms of the illness can vary widely, ranging from high fever, chills, cough, and difficulty breathing to chest pain, stiff neck, rapid heart rate, sensitivity to light, and confusion. The diagnosis of invasive pneumococcal disease typically involves a comprehensive combination of clinical findings, imaging studies, and laboratory tests. The healthcare provider often recommends blood cultures to identify the presence of pneumococcus in the bloodstream. Furthermore, chest X-rays might be performed to visualize any potential lung involvement in individuals suffering from the ailment. Additionally, samples from numerous other affected sites, such as cerebrospinal fluid in cases of meningitis, could be analyzed to confirm the presence of the bacterium and guide appropriate treatment.
The increasing cases of bacterial infections, in which the microorganism invades the bloodstream or tissues and fluids surrounding the spinal cord and brain, are primarily driving the invasive pneumococcal disease market. In addition to this, the inflating utilization of effective medication, including broad-spectrum antibiotics, such as penicillin, cephalosporins, macrolides, etc., to combat the ailment and prevent its spread, is also creating a positive outlook for the market. Moreover, the widespread adoption of pneumococcal vaccines, encompassing conjugate and polysaccharide vaccines, is further bolstering the market growth. These therapeutic vaccines aid in safeguarding individuals of various age groups against numerous strains of the bacterium, thereby reducing the incidence of severe pneumococcal infections. Apart from this, the rising application of supportive therapies, such as oxygen supplementation, fluid management, respiratory support, etc., for enhancing treatment outcomes in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced diagnostic tools like polymerase chain reaction (PCR), which can help in early detection and accurate characterization of the ailment, is also augmenting the market growth. Furthermore, numerous ongoing advancements in the field of innovative therapeutic techniques, with a focus on antibody-mediated therapies and antitoxin interventions, are expected to drive the invasive pneumococcal disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the invasive pneumococcal disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for invasive pneumococcal disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the invasive pneumococcal disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the invasive pneumococcal disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the invasive pneumococcal disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current invasive pneumococcal disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the invasive pneumococcal disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the invasive pneumococcal disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the invasive pneumococcal disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of invasive pneumococcal disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of invasive pneumococcal disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of invasive pneumococcal disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with invasive pneumococcal disease across the seven major markets?
What is the size of the invasive pneumococcal disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of invasive pneumococcal disease?
What will be the growth rate of patients across the seven major markets?
Invasive Pneumococcal Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for invasive pneumococcal disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the invasive pneumococcal disease market?
What are the key regulatory events related to the invasive pneumococcal disease market?
What is the structure of clinical trial landscape by status related to the invasive pneumococcal disease market?
What is the structure of clinical trial landscape by phase related to the invasive pneumococcal disease market?
What is the structure of clinical trial landscape by route of administration related to the invasive pneumococcal disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INVASIVE PNEUMOCOCCAL DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INVASIVE PNEUMOCOCCAL DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INVASIVE PNEUMOCOCCAL DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 INVASIVE PNEUMOCOCCAL DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INVASIVE PNEUMOCOCCAL DISEASE - UNMET NEEDS
10 INVASIVE PNEUMOCOCCAL DISEASE - KEY ENDPOINTS OF TREATMENT
11 INVASIVE PNEUMOCOCCAL DISEASE - MARKETED PRODUCTS
11.1 List of Invasive Pneumococcal Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 INVASIVE PNEUMOCOCCAL DISEASE - PIPELINE DRUGS
12.1 List of Invasive Pneumococcal Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. INVASIVE PNEUMOCOCCAL DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INVASIVE PNEUMOCOCCAL DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INVASIVE PNEUMOCOCCAL DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Invasive Pneumococcal Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Invasive Pneumococcal Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Invasive Pneumococcal Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Invasive Pneumococcal Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Invasive Pneumococcal Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Invasive Pneumococcal Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Invasive Pneumococcal Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Invasive Pneumococcal Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
16 INVASIVE PNEUMOCOCCAL DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INVASIVE PNEUMOCOCCAL DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INVASIVE PNEUMOCOCCAL DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INVASIVE PNEUMOCOCCAL DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 INVASIVE PNEUMOCOCCAL DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INVASIVE PNEUMOCOCCAL DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 INVASIVE PNEUMOCOCCAL DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INVASIVE PNEUMOCOCCAL DISEASE - UNMET NEEDS
10 INVASIVE PNEUMOCOCCAL DISEASE - KEY ENDPOINTS OF TREATMENT
11 INVASIVE PNEUMOCOCCAL DISEASE - MARKETED PRODUCTS
11.1 List of Invasive Pneumococcal Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 INVASIVE PNEUMOCOCCAL DISEASE - PIPELINE DRUGS
12.1 List of Invasive Pneumococcal Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. INVASIVE PNEUMOCOCCAL DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. INVASIVE PNEUMOCOCCAL DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 INVASIVE PNEUMOCOCCAL DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Invasive Pneumococcal Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Invasive Pneumococcal Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Invasive Pneumococcal Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Invasive Pneumococcal Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Invasive Pneumococcal Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Invasive Pneumococcal Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Invasive Pneumococcal Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Invasive Pneumococcal Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Invasive Pneumococcal Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Invasive Pneumococcal Disease - Access and Reimbursement Overview
16 INVASIVE PNEUMOCOCCAL DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 INVASIVE PNEUMOCOCCAL DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 INVASIVE PNEUMOCOCCAL DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
